A61K47/24

OIL-IN-WATER EMULSION FORMULATIONS FOR DELIVERY OF ACTIVE OR THERAPEUTIC AGENTS

Provided herein are methods and compositions for the delivery of at least two active, therapeutic, or pharmaceutical agents in an oil-in-water emulsion, wherein at least one agent is delivered in the hydrophobic phase of the emulsion and at least one agent is delivered in the aqueous phase of the emulsion.

OIL-IN-WATER EMULSION FORMULATIONS FOR DELIVERY OF ACTIVE OR THERAPEUTIC AGENTS

Provided herein are methods and compositions for the delivery of at least two active, therapeutic, or pharmaceutical agents in an oil-in-water emulsion, wherein at least one agent is delivered in the hydrophobic phase of the emulsion and at least one agent is delivered in the aqueous phase of the emulsion.

COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION
20230233682 · 2023-07-27 ·

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION
20230233682 · 2023-07-27 ·

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

Orally bioavailable lipid-based constructs
11517529 · 2022-12-06 · ·

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

Orally bioavailable lipid-based constructs
11517529 · 2022-12-06 · ·

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

MULTIPLE NUTRIENT LIPOSOMAL SUPPLEMENT AND METHODS OF MANUFACTURING THE SAME
20230233467 · 2023-07-27 · ·

Compositions and methods for increasing absorption of nutrients by a body. A composition includes a liposome comprising a lipid bilayer, wherein the liposome comprises an internal core. The composition includes a nutrient payload disposed within the liposome. The nutrient payload comprises a plurality of different supplement nutrients comprising one or more of a vitamin, mineral, extract, enzyme, or amino acid.

MULTIPLE NUTRIENT LIPOSOMAL SUPPLEMENT AND METHODS OF MANUFACTURING THE SAME
20230233467 · 2023-07-27 · ·

Compositions and methods for increasing absorption of nutrients by a body. A composition includes a liposome comprising a lipid bilayer, wherein the liposome comprises an internal core. The composition includes a nutrient payload disposed within the liposome. The nutrient payload comprises a plurality of different supplement nutrients comprising one or more of a vitamin, mineral, extract, enzyme, or amino acid.

LIPID DEPOT FORMULATIONS

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

LIPID DEPOT FORMULATIONS

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.